While Human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and is overexpressed in 30% of invasive breast cancer [5,6,97], HER2+ breast cancer is associated with higher early survival [5]. Here, ERBB2 is linked to breast carcinoma.